Neurocrine biosciences, inc. (NBIX)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues:
Revenues

237,100

244,013

222,094

183,580

138,400

131,492

151,757

96,905

71,086

-

60,774

6,335

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Sponsored research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

13,959

1,369

1,540

2,029

1,873

2,396

2,919

3,274

5,210

1,286

Total revenues

-

-

-

-

-

-

-

-

-

-

-

6,335

0

-

0

0

15,000

0

0

0

19,769

0

0

0

0

730

729

730

730

21,947

9,357

10,569

11,267

11,110

41,634

12,157

12,512

14,448

4,643

Operating expenses:
Cost of sales

2,100

2,491

2,229

1,608

1,100

1,534

1,551

854

950

760

433

61

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

58,300

55,377

45,278

61,687

37,700

34,357

35,482

36,988

48,947

-4,386

22,463

21,868

51,882

22,583

20,942

26,863

23,903

21,809

24,388

18,719

16,575

15,498

12,194

10,161

8,572

8,918

9,490

10,527

10,313

9,097

9,860

8,818

9,388

8,002

7,456

8,176

7,317

8,227

7,283

Acquired in-process research and development

-

-

-

-

113,100

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Acquired in-process research and development

-

-

-

5,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Selling, general and administrative

117,800

101,249

84,489

80,824

87,500

68,980

60,401

60,915

58,636

56,309

43,873

41,674

28,050

23,668

17,494

14,965

11,954

8,939

11,456

6,603

5,482

4,970

4,663

4,200

4,153

3,342

3,245

3,370

3,392

3,311

3,324

3,131

3,671

2,668

3,825

2,809

3,156

3,635

3,116

Cease-use expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

135

-

-

-7

-87

76

100

120

134

Total operating expenses

178,200

195,289

131,996

149,119

239,400

109,621

97,434

98,757

108,533

82,683

66,769

63,603

79,932

46,251

38,436

41,828

35,857

30,748

35,844

25,322

22,057

20,468

16,857

14,361

12,725

12,260

12,735

13,897

13,705

13,365

13,319

11,949

13,059

10,663

11,194

11,061

10,573

11,982

10,533

Operating income (loss)

58,900

48,724

90,098

34,461

-101,000

21,871

54,323

-1,852

-37,447

11,834

-5,995

-57,268

-79,932

-46,251

-38,436

-41,828

-20,857

-30,748

-35,844

-25,322

-2,288

-20,468

-16,857

-14,361

-12,725

-11,530

-12,006

-13,167

-12,975

8,582

-3,962

-1,380

-1,792

447

30,440

1,096

1,939

2,466

-5,890

Other (expense) income:
Gain/(loss) on sale/disposal of assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-9

14

3

-

0

0

9

0

1

5

-10

-1

6

19

13

7

0

0

25

58

86

18

80

34

53

Deferred gain on real estate

-

-

-

-

-

-

-

-

-

-

-

879

879

-

853

854

853

838

828

829

830

812

805

805

804

789

781

781

782

766

759

759

758

744

736

737

736

715

715

Interest expense

8,200

8,083

8,038

7,942

7,900

7,763

7,672

7,591

7,504

7,419

7,337

4,767

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized losses (gains) on equity securities

-16,500

-7,202

-28,450

20,965

1,700

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Investment income and other, net

4,700

5,205

4,797

4,607

4,600

4,700

4,113

3,530

3,133

4,237

2,207

1,171

727

4,160

705

680

737

584

581

506

257

197

176

167

89

85

93

121

103

130

123

115

121

77

102

120

119

118

-65

Other (expense) income, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

3

-

15

-5

4

2

5

2

5

2

5

18

5

8

-

35

Total other expense, net

-20,000

-10,080

-31,691

17,630

-1,600

-3,063

-3,559

-4,061

-4,371

-4,940

-5,130

-2,717

1,606

1,592

1,549

1,548

1,593

1,433

1,409

1,335

1,096

1,024

982

980

883

888

875

925

900

908

884

879

906

884

942

880

943

867

738

Income (loss) before provision for (benefit from) income taxes

38,900

38,644

58,407

52,091

-102,600

18,808

50,764

-5,913

-41,818

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Provision for (benefit from) income taxes

1,500

4,659

4,618

753

-500

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss)

37,400

33,985

53,789

51,338

-102,100

18,078

50,764

-5,913

-41,818

6,894

-11,125

-59,985

-78,326

-44,659

-36,887

-40,280

-19,264

-29,315

-34,435

-23,987

-1,192

-19,444

-15,875

-13,381

-11,842

-10,642

-11,131

-12,242

-12,075

9,490

-3,078

-501

-886

1,331

31,382

1,976

2,882

3,333

-5,152

Other comprehensive income (loss):
Net income (loss)

37,400

33,985

53,789

51,338

-102,100

18,078

50,764

-5,913

-41,818

6,894

-11,125

-59,985

-78,326

-44,659

-36,887

-40,280

-19,264

-29,315

-34,435

-23,987

-1,192

-19,444

-15,875

-13,381

-11,842

-10,642

-11,131

-12,242

-12,075

9,490

-3,078

-501

-886

1,331

31,382

1,976

2,882

3,333

-5,152

Unrealized gain (loss) on marketable securities

-2,800

-194

961

878

1,700

124

753

888

-1,847

-1,316

179

-478

83

-131

-148

149

789

-368

-205

-225

98

-70

-81

68

-199

14

35

0

-42

-21

162

-16

-40

72

-140

31

-2

-

-

Comprehensive income (loss)

34,600

33,791

54,750

52,216

-100,400

18,202

51,517

-5,025

-43,665

5,578

-10,946

-60,463

-78,243

-44,790

-37,035

-40,131

-18,475

-29,683

-34,640

-24,212

-1,094

-19,514

-15,956

-13,313

-12,041

-10,628

-11,096

-12,242

-12,117

9,469

-2,916

-517

-926

1,403

31,242

2,007

2,880

-

-

Net income (loss) per share:
Net income (loss) per share, basic

0.40

0.37

0.59

0.56

-1.12

-

0.56

-0.07

-

-

-0.13

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.02

0.57

0.04

0.05

0.06

-0.09

Net income (loss) per share, diluted

0.39

0.41

0.56

0.54

-1.12

-

0.52

-0.07

-

-

-0.13

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.02

0.56

0.04

0.05

0.06

-0.09

Net loss per share, basic and diluted

-

-

-

-

-

-

-

-

-0.47

-

-

-0.68

-0.90

-

-0.43

-0.46

-0.22

-

-0.40

-0.28

-0.01

-

-0.21

-0.18

-0.17

-

-0.17

-0.18

-0.18

-

-0.05

-0.01

-0.01

-

-

-

-

-

-

Shares used in the calculation of net income (loss) per share:
Weighted average common shares outstanding, basic

92,600

92,160

91,859

91,389

91,100

-

90,555

90,100

-

-

88,325

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

55,264

55,248

55,209

54,983

54,844

54,836

Weighted average common shares outstanding, diluted

97,000

100,975

96,074

94,779

91,100

-

96,798

90,100

-

-

88,325

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

56,462

56,378

56,434

56,114

55,648

54,836

Weighted average common shares outstanding, basic and diluted

-

-

-

-

-

-

-

-

89,526

-

-

88

87,283

-

86,784

86,694

86,497

-

85,856

85,518

80,349

-

75,948

75,879

70,260

-

67,199

66,799

66,600

-

66,342

66,309

63,409

-

-

-

-

-

-

Product sales, net
Revenues

231,100

237,862

198,094

180,544

136,400

130,326

111,291

96,905

71,086

-

45,774

-

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration revenue
Revenues

6,000

6,151

24,000

3,036

2,000

-

40,466

-

-

-

15,000

-

-

0

0

0

15,000

0

0

0

19,769

0

0

0

0

730

729

730

730

7,988

7,988

9,029

9,238

9,237

39,238

9,238

9,238

9,238

3,357